Primary dysfunction (PDF) still occurs after orthotopic liver transplantation (OLT). Celsior solution (CS) might offer some advantages over the conventional University of Wisconsin (UW) solution for organ preservation, but to date, this has not been prospectively evaluated in the context of OLT. In this prospective, randomized, multicenter, pilot study, 215 potential liver donors were enrolled and randomized. In 42 cases, the livers were unsuitable for transplantation; therefore, 173 randomized livers ultimately were implanted after perfusion and cold preservation with CS (n ‫؍‬ 83) or UW solution (n ‫؍‬ 90). In accord with the indications of the CS manufacturing company, total CS infusion volume was 90 mL/kg, greater than that of UW solution (60 mL/kg). The main aim of the study is to compare the prevalence of PDF between the two groups. Donor and recipient variables were similar in the two groups. Episodes of PDF were numerically lower in the CS (2.4%) than UW group (7.8%), but the difference was not statistically significant. There was a trend toward a lesser need for early re-OLT (<30 days) in the CS group (P ‫؍‬ .0507), but again, no statistically significant difference emerged. Overall and time-differentiated postoperative deaths also were similar. One-year actuarial patient (UW, 89% v CS, 87%) and graft (UW, 83% v CS, 85%) survival rates were similar. In conclusion, CS was similar to UW solution as a preservation solution in the clinical setting of OLT at the infusion volumes described, although some theoretical advantages of CS composition suggest that CS might prove a valid alternative to UW preservation solution in multiorgan harvesting, including the liver. A study on a larger patient basis is needed. (Liver Transpl 2003;9:814-821.)
O rthotopic liver transplantation (OLT) has become a standard treatment for end-stage liver disease. Although significant improvements have been made in the surgical, anesthesiological, and pharmacological fields, such problems as graft failure and postoperative multiorgan complications remain to be solved. 1, 2 Although it is less frequent than for other organs, such as the kidney, primary graft dysfunction (PDF) after OLT unrelated to any direct surgical, immunologic, or other complications still occurs in a significant number of recipients. [3] [4] [5] [6] [7] Grafts with initial poor function (IPF) have a greater than normal graft failure rate in the first 3 months after OLT. 1 One of the causes of PDF is poor organ quality at the time of OLT, which can depend on the condition of the donor, cold ischemia time (CIT), and organ preservation method.
University of Wisconsin (UW) solution has been widely accepted as the gold standard for liver graft preservation, replacing the previously used Euro-Collins solution (Fresenius AG, Bad Homburg, Germany). 8 A new preserving solution, Celsior solution (CS) (SangStat Medical Corporation, Fremont, CA), 9 recently has become available that might theoretically offer a new means for improving graft preservation quality and probably also graft outcome. CS is an extracellular type of solution initially used successfully in heart transplantation 9 and more recently shown to be an effective alternative to UW solution in preserving such thoracic and abdominal organs as the lung, 10 kidney, 11 small intestine, 12 and pancreas. 13 Given its low viscosity and antioxidant and antiedema properties, 9 CS might be particularly suitable for preserving livers; however, data from the clinical setting of OLT have been scanty to date. 14 The present study is designed to compare the efficacy of CS and UW solution as a preservation solution for liver allografts in the context of a prospective, randomized, multicenter, pilot study.
Methods

Patients
From March 1999 to November 2001, a total of 215 potential liver donors were considered in this study and randomly assigned to two groups. Three liver transplant centers were involved (the Universities of Bologna, Padova, and Pisa, Italy). The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the appropriate institutional review committee of each center.
All donors older than 14 years and potentially eligible for liver donation according to the centers' policies were included in the study. In particular, all donors were considered eligible with the following exclusion criteria: positivity for human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or cytomegalovirus immunoglobulin M; diagnosis of malignancies; severe liver trauma; or evidence of cirrhosis, sepsis, severe acute pancreatitis, or active drug addiction.
We also excluded split livers (in situ, ex situ), reduced livers, domino liver transplantation, living related donor livers, and sent livers (liver harvested by teams of different centers and subsequently sent for transplantation to centers participating in the study).
Recipients were males and females aged 14 to 70 years with end-stage liver disease undergoing their first OLT. Cases of multiorgan transplantation or previous OLT were excluded. Informed consent in writing was obtained from each transplant recipient.
Randomization
At each center, donor livers were randomly assigned to CS or UW solution according to a computer-defined randomization list.
Randomization was performed immediately after a telephone call was received from the Italian organ-sharing organizations (North Italian Transplant program and Associazone InterRegionale Trapianti) to notify us that a potential cadaveric liver donor was available. This meant that all livers "accepted" at the time of the telephone call, but subsequently not transplanted because they were judged to be unsuitable for grafting at the time of harvesting or at back-table biopsy, were included in the randomization list. In 42 cases (22 cases randomized to the CS group; 20 cases, the UW group), livers were considered unsuitable for OLT because of high-grade steatosis (steatosis Ͼ 60% at back-table biopsy), donor hemodynamic instability, or other causes. No statistically significant differences were found between discarded grafts in the CS and UW groups ( Table 1 ). The remaining 173 livers were transplanted into 173 recipients and form the object of the present study (CS group, 83 livers; UW group, 90 livers).
Technical Aspects
After randomization, donor liver harvesting was performed using the conventional technique. Briefly, after aorta and superior mesenteric vein cannulation, donor livers were perfused in situ by gravity through the aorta and portal vein with CS or UW solution at 4°C. Total perfusion volumes were decided for each solution according to standard manufacturing company indications and our previous clinical experience. Infusion volumes therefore were different in the CS and UW groups: CS, 30 mL/kg through the portal vein and 60 mL/kg through the aorta; and UW solution, 30 mL/kg through the portal vein and 30 mL/kg through the aorta.
Approximately 60% of the volume of both solutions was rapidly infused (in 10 to 15 minutes) after aortic cross-clamping. Perfusion then was slowed for the remaining 40% of solution until the end of harvesting (20 to 40 minutes). After hepatectomy, donor livers were perfused further at the back table with CS or UW solution (700 mL through the portal vein and 300 mL through the hepatic artery) and stored in conventional bags containing the same solution at 4°C until transplantation.
OLT was performed according to the classic Starzl technique (13% of UW group and 16% of CS group) or preserving the retrohepatic vena cava (piggyback technique: 87% of UW group and 84% of CS group). Transplant recipients were administered dual-or triple-drug immunosuppressive therapy, which included cyclosporine or tacrolimus combined with corticosteroids with or without azathioprine or mycophenolate mofetil, according to practice at the center. Post-OLT liver biopsy was performed only when clinically indicated. Patients were followed up for a minimum of 1 year, recording patient, graft survival, liver function test results, and prevalence of biopsy-proven acute cellular rejection in the first 12 months after surgery.
Outcome
The main measures of outcome were PDF resulting from the sum of primary nonfunction (PNF) and IPF defined according to Ploeg et al. 6 PNF is non-life-sustaining function of the graft leading to death or re-OLT within 7 days and documented by hepatic cytolysis and rapidly increasing serum transaminase levels, little or no bile production, a severe liverrelated coagulation deficit, high lactate levels, hypoglycemia, the need for aggressive ventilatory support and circulatory support with catecholamines, and the onset of acute renal failure and multiorgan failure. IPF is defined as an aspartate aminotransferase (AST) level greater than 2,000 IU/L and prothrombin time greater than 16 seconds postoperative days 2 through 7, as suggested by Ploeg et al. 6 Postoperative findings were recorded, including days in the intensive care unit (ICU) and biochemical liver function parameters (total and direct bilirubin, serum AST, alanine aminotransferase, ␥-glutamyltransferase, alkaline phosphatase, albumin, total protein, and lactate dehydrogenase levels and prothrombin and partial thromboplastin times) and kidney function (serum creatinine and blood urea nitrogen levels and urine output) up to 90 days after OLT. Preoperative findings relating to donor and recipient features and CIT and warm ischemia time (WIT) also were monitored and considered for analysis.
End Points
We defined PDF as the main end point of the study.
Statistical Analysis
All demographic and baseline variables are described by statistical characteristics. Categorical data are described by frequency and percentage. Continuous data are described by mean and SD. For eight patients (4.6%; three cases with CS and five cases with UW solution), some cytolysis and/or cholestasis parameters were missing. These cases were excluded from the final analysis of biochemical parameters. Differences between study groups were assessed by means of different inferential tests, depending on the type of data. Categorical variables were analyzed using Chi-squared test (Fisher's exact test), with a significance level of .05. Continuous variables were analyzed using Student's parametric t-test, with a significance level of .05.
Results
Donor and Recipient Characteristics
Distribution of the main donor liver variables in the two study groups is listed in Table 2 . Donor livers randomized to CS or UW solution were similar for gender, age, cause of death, length of stay in the ICU before death, amount of dopamine infused to maintain blood pressure, and percentage of steatosis.
Recipient demographic and clinical characteristics are listed in Table 3 . Patients were distributed evenly in terms of gender and age in the two groups. Indications for OLT were similar in the two groups, including percentages of virus-related cirrhosis and alcoholic cirrhosis. There was a tendency for the prevalence of cholestatic disease and primary hepatocellular carcinoma to be greater in the CS than UW group, but the difference did not reach statistical significance. At OLT, recipient Child-Pugh status did not differ significantly between the two study groups. Similarly, no difference was found in the other recipient variables considered (Table 3) .
Pre-OLT and Peri-OLT Ischemia Times
Median CITs were 7.4 hours (range, 3 to 11 hours) in the CS group and 7.3 hours (range, 4 to 12 hours) in the UW group. Median WITs (time on the operating table up to portal vein reperfusion) were 50.0 minutes (range, 21 to 100 minutes) and 49.5 minutes (range, 20 to 80 minutes) in the CS-and UW solution-preserved organs, respectively. CITs and WITs did not differ significantly between the two groups.
Post-OLT Outcome
Early postoperative graft function is listed in Table 4 . In particular, no cases of PNF occurred in the CS group, whereas one case was reported in the UW group.
The CS and UW groups also were compared in terms of main postoperative biochemical parameters. As shown in Figure 1 , there was no statistically significant difference between groups for liver graft and kidney function indicators during the first 7 days or thereafter up to 90 days after surgery (data not shown).
There was no difference between the two groups in terms of number of patients who underwent re-OLT in the first year after surgery (Table 5) . Analysis performed at different times up to 1 year after surgery showed a borderline statistically significant lower number of reOLTs within 30 days in the CS than UW group (P ϭ .0507). Causes of early re-OLT (Ͻ30 days) in the UW group (nine cases) were PNF (one case), IPF (one case), acute outflow obstruction (two cases), acute rejection unresponsive to immunosuppression (one case), and hepatic artery thrombosis (four cases). In the CS group, the two cases of early re-OLT were both caused by hepatic artery thrombosis.
One-year actuarial patient survival (87% and 89% in the CS and UW groups, respectively; Fig. 2 ) and 1-year graft survival in recipients of CS-versus UW solution-preserved organs (85% v 83%; Fig. 3) were not statistically significant.
Overall and time-related postoperative deaths were similar in the two groups (Table 5 ). Recipients of CSperfused organs died of multiorgan failure (four cases), sepsis (two cases), vascular events (two cases), acute renal failure (one case), and neurological events (one case). In the UW group, death was caused by multiorgan failure (three cases), sepsis (three cases), myocardial infarction (one case), respiratory insufficiency (one case), relapsing hepatitis (one case), acute renal failure (one case), and cerebrovascular events (one case).
No statistically significant differences concerning neurological (pontine myelolysis), vascular (portal and arterial thrombosis, vascular stenosis), and biliary (leak, anastomotic stenosis) complications were observed between the two groups.
Discussion
Ischemia-reperfusion injury still represents a relevant cause of morbidity after OLT. In particular, PDF, including PNF and IPF of the graft, remains a severe complication after the operation. PDF is associated with longer ICU stays, greater infection rates, and significantly lower 1-and 6-month patient and graft survival rates. 3, 4 The recent adoption in clinical practice of a more aggressive approach to organ recruitment has introduced a greater potential risk for postoperative graft dysfunction. Although there is a large body of evidence to show that older donors and fatty livers significantly increase the incidence of PDF, the present donor shortage has encouraged the use of so-called marginal livers and grafts from elderly donors (Ͼ65 years). Moreover, the progressive clinical expansion of liver-splitting techniques has introduced additional new variables relating to longer harvesting times and parenchymal handling that may influence postoperative graft recovery. UW solution 15, 16 is now considered the standard preservation solution for liver, kidney, and pancreas transplantation, but its high potassium content has been accused of potentially causing calcium-associated contracture, leading to contraction of glomerular capillaries after kidney transplantation, but also endothelial impairment and biliary tract damage in livers transplanted after lengthy CITs. [17] [18] [19] A great deal of interest has consequently focused on the new and potentially more effective preservation solutions for use in OLT.
CS is a high-sodium, low-potassium, low-viscosity preservation solution with extracellular iso-osmotic characteristics specifically formulated for heart preservation. The formula for CS is listed in Table 6 and compared with UW solution.
CS is designed to minimize hypothermia-induced cell swelling and interstitial edema caused by the presence of such membrane-impermeable substances as mannitol and lactobionate. It also is characterized by a marked buffer capacity caused by the presence of 30 mmol of histidine. 18 From this perspective, UW solution differs from CS in that it contains raffinose, characterized by a greater molecular weight than mannitol.
CS also contains oxygen radical scavengers, with reduced glutathione, in particular, but mannitol and histidine also have a part in preventing oxidative injury related to postreperfusion free radical production. Conversely, the rapidly oxidized glutathione in shelf-stored UW solution definitely lacks this important protective effect.
The role of glutamate in CS is to yield adenosine triphosphate under anaerobic conditions, preventing intracellular acidosis and permitting the energy-dependent systems that normally maintain calcium, sodium, and potassium homeostatic functions. 19 Some preliminary reports recently suggested that CS is effective for preserving not only thoracic organs, but also livers, in both the preclinical and clinical settings. [20] [21] [22] [23] According to the experience of Audet et al 24 in a pig model of OLT, liver grafts perfused with CS performed similarly to those perfused with UW solution in terms of postoperative animal and graft survival. Ohwada et al 25 report better results with liver grafts perfused with CS than with UW solution in a canine OLT model based on non-heart-beating donors.
CS has been tested for liver preservation in the clinical setting at a number of centers, but without a randomized pattern, as described by Hefty et al 15 and subsequently by Maggi et al. 14 All these studies reported a good safety-efficacy profile for CS in clinical OLT, with no substantial differences with respect to the commonly used UW solution.
To the best of our knowledge, this is the first prospective randomized study comparing UW solution and CS for graft preservation in OLT. The study is designed to compare the two solutions on a hypothesis of their equivalence in terms of their ability to preserve liver grafts for transplantation.
Our choice to use different perfusion volumes (CS, 90 mL/kg total perfusion; UW solution, 60 mL/kg total perfusion) is because in the CS group, we adopted the infusion volumes prescribed by the CS manufacturing company. Furthermore, the same amount of CS was used in our centers in the preliminary clinical applications preceding the present study. We believe the use of lower CS volumes in the present randomized trial would not have been ethical for patients included in the CS group. However, such a volume difference has to be taken into account as a potential bias in the evaluation of results. Sample numbers were deliberately limited to avoid prolonging enrollment times, whereas involving only a few centers in the study to keep procedural differences to a minimum.
The first point to note is that our two groups were statistically balanced in terms of donor graft and patient variables. Moreover, no statistically significant difference emerged between the two groups regarding the number of livers initially randomized, but subsequently not implanted. Therefore, even if this is not a blinded study, the solution type used for preservation does not seem to have influenced the transplant teams in their decision to use or not use the liver.
More importantly, the prevalence of major risk factors for post-OLT graft dysfunction, e.g., percentage of steatosis, natremia at harvesting, CIT, and WIT, were similar between the two study groups.
An additional point to note is that none of the patients in the CS group had post-OLT PNF as defined by Ploeg et al. 6 Considering the overall prevalence of PDF, 7.8% of PDF was observed for UW solution, and 2.4%, for CS. These findings are consistent with preclinical and clinical studies confirming the effectiveness of CS for preserving livers for transplantation, at least in the range of CITs observed in the study (range, 4 to 12 hours). This study did not assess CS effectiveness in the clinical setting of prolonged ischemia times. However, no conclusive statements can be made on the strength of the comparison of PDF prevalence between the two groups because the relatively low number of cases of PDF in the entire series is a major limiting factor.
The marked trend toward statistical significance (P ϭ .0507) for a greater prevalence of early re-OLT in the UW group needs to be confirmed in a larger series of patients.
The overall prevalence of PDF and early postoperative graft loss was lower than in previously reported series irrespective of the preservation solution used; the relatively short CITs and WITs combined with an accurate donor-recipient matching policy may justify our good results.
No adverse events potentially related to the preservation solution, with particular reference to postreperfusion hemodynamic instability and/or arrhythmia, were observed in the entire series.
Regarding post-OLT biochemical parameters, although Cofer et al 8 reported that AST level is the best indicator of ischemic preservation injury among the usual parameters recorded in the early postoperative course, in our study, the great variability in these parameters (especially in the first 48 hours after OLT) may have affected its sensitivity in detecting differences between groups. In this perspective, CS clearly showed its protective effect against ischemia-related hepatocellular damage, even in this randomized setting. Judging from prothrombin time and albumin values, the functional recovery of liver synthesis was similar in the two groups. More importantly, total bilirubin levels (regarded as one of the best overall indicators of graft functional recovery) changed in much the same way in the postoperative course of the two groups. There was no pathological comparison relative to ischemia-reperfusion injury in the present study because none of the centers taking part adopted a postoperative biopsy protocol for ethical reasons.
We conclude that CS is similar to UW solution as a preservation solution in the clinical setting of OLT, taking into account that perfusion volumes were greater in the CS group in this study. The potentially greater protective effect of CS has to be confirmed by a more sensitive study, but CS seems to offer a number of advantages over UW solution, i.e., lower viscosity, no need for prereperfusion flush, and suitability for both chest and abdominal organ harvesting.
Additional studies on a larger patient series are needed to show any superiority of CS over UW solution and to test its potential for extending the CIT in clinical OLT.
